21,234 Shares in Health Catalyst, Inc. (NASDAQ:HCAT) Bought by Semanteon Capital Management LP

Semanteon Capital Management LP purchased a new position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 21,234 shares of the company’s stock, valued at approximately $197,000.

Other large investors have also recently bought and sold shares of the company. Stratos Wealth Partners LTD. acquired a new stake in shares of Health Catalyst in the 3rd quarter worth $114,000. MQS Management LLC acquired a new stake in shares of Health Catalyst in the 3rd quarter worth $116,000. Versor Investments LP acquired a new stake in shares of Health Catalyst in the 3rd quarter worth $117,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Health Catalyst by 23.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,072 shares of the company’s stock valued at $140,000 after purchasing an additional 2,817 shares during the period. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Health Catalyst in the third quarter valued at about $166,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Evercore ISI reduced their price objective on shares of Health Catalyst from $11.00 to $10.00 and set an “outperform” rating for the company in a research note on Friday, February 23rd. Barclays assumed coverage on shares of Health Catalyst in a research note on Wednesday, January 3rd. They issued an “overweight” rating and a $14.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research note on Wednesday, April 10th. Piper Sandler reiterated an “overweight” rating and issued a $15.00 price objective (down previously from $17.00) on shares of Health Catalyst in a research note on Friday, February 23rd. Finally, KeyCorp reiterated a “sector weight” rating on shares of Health Catalyst in a research note on Wednesday, April 10th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $12.10.

Health Catalyst Price Performance

NASDAQ:HCAT opened at $6.03 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.42 and a current ratio of 4.42. The firm has a 50-day moving average price of $7.39 and a two-hundred day moving average price of $8.27. Health Catalyst, Inc. has a twelve month low of $5.45 and a twelve month high of $14.37.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.06. The business had revenue of $75.08 million during the quarter, compared to the consensus estimate of $73.67 million. Health Catalyst had a negative net margin of 39.92% and a negative return on equity of 12.19%. Analysts expect that Health Catalyst, Inc. will post -0.47 earnings per share for the current fiscal year.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.